Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical....More>>>
After Republican leaders in the House of Representatives decided to pull their healthcare bill last week, President Donald Trump indicated that his focus would most likely shift to tax reform. While we don’t know anything official about what a finalized tax reform bill might look like, we do know what the president promised during his campaign and how it compares to the current GOP platform.
U.S. equities finished near the unchanged line on Tuesday after recovering from deeper intraday losses.
Geopolitical tensions were in focus, with attention on North Korea and Syria. President Trump tweeted that Pyongyang was “looking for trouble” and that the United States would “solve the problem” if China didn’t help. Concerning Syria, the G7 countries failed....More>>>
Celgene (NASDAQ: CELG) is a more than $80 billion biotech company that hurt its investors in late October, after a difficult environment forced the company to cut its growth forecasts. However, the company operates in growing markets, and still has what’s arguably the best portfolio of assets in the biotech industry. Its market-leading portfolio, especially after its acquisition of Impact....More>>>
Yesterday, our Elite Opportunity Pronewsletter suggested the ProShares UltraShort Nasdaq Biotech (NASDAQ: BIS) and Direxion Daily S&P Biotech Bear 3X Shares (NYSEARCA: LABD) as ways to short biotech onshort termweakness in the sector, but our suggestion comes with a long termcaveat:
We’ve done well with our individual small biotech plays over the last several months. However, depending....More>>>
Shares of Gilead Sciences (GILD) have after the biotech giant reported better than expected earnings but whiffed on 2017 guidance.
Agence France-Presse/Getty Images
Gilead reported a profit of $2.70 a share, topping forecasts of $2.61 a share, on sales of $7.32 billion, beating estimates for $7.14 billion. That’s where the good news stopped, however. Gilead predicted 2017 product....More>>>
Recently, Ziopharm Oncology (NASDAQ:ZIOP) gave an update on its first-quarter 2018 earnings report. It noted that a phase 3 study would be paused for the time being. The biotech is now pointing to its other mid-stage studies as being more prominent than the phase 3 study that was supposed to start soon treating patients with recurrent glioblastoma (brain cancer). I have to agree with this assessment,....More>>>
Eight companies aim to raise a combined $3.5 billion in the short holiday week. Four Chinese IPOs lead the way, headlined by iQIYI (Pending:IQ), planning to raise over $2 billion in the largest Chinese offering since Alibaba (NYSE:BABA) in 2014. It is joined by another large Chinese online video IPO, Bilibili (Pending:BILI). The stream of Chinese deals comes just one week after the tariff scare....More>>>
Shares of biopharma Nektar Therapeutics (NASDAQ:NKTR) dropped over 11% today after the company released an abstract to be presented at the American Society of Clinical Oncology annual meeting next month that contained a disappointing update for an ongoing clinical trial.
The latest interim data analysis for a phase 1/2 trial evaluating a combination therapy of the company’s....More>>>
Warren Buffett says he’s sticking by embattled bank Wells Fargo, isn’t ready to jump into the risky business of insuring “cyber”catastrophes and all but ruled out paying a one-time special dividend to shareholders despite sitting on nearly $109billion in idle cash.
The legendary investor, and chairman and CEO of Berkshire Hathaway, now 87 years old,also took time....More>>>